A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer

LESSONS LEARNED. Single‐agent selinexor has limited activity in heavily pretreated patients with metastatic triple‐negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side‐effect profile consistent with previous clinical trials. Future studies of selinex...

Descripción completa

Detalles Bibliográficos
Autores principales: Shafique, Michael, Ismail‐Khan, Roohi, Extermann, Martine, Sullivan, Dan, Goodridge, Dawn, Boulware, David, Hogue, Deanna, Soliman, Hatem, Khong, Hung, Han, Hyo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656474/
https://www.ncbi.nlm.nih.gov/pubmed/30996012
http://dx.doi.org/10.1634/theoncologist.2019-0231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656474/
https://www.ncbi.nlm.nih.gov/pubmed/30996012
http://dx.doi.org/10.1634/theoncologist.2019-0231

Ejemplares similares